In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript March 19, 2026 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were ...

Moby summary of Relmada Therapeutics, Inc.'s Q4 2025 earnings call ...

Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorabl ...

Henlius (2696.HK) today announced its annual results for the year ended December 31, 2025. During the reporting ...

In a recent conference call, Relmada Therapeutics provided an update on its fourth quarter and full year 2025 financial results. The company reported significant progress in its lead program, NDV-01, ...

Neoadjuvant capecitabine-oxaliplatin chemotherapy did not improve three-year disease-free survival compared to upfront surgery in locally advanced colon cancer. 2. An exploratory subgroup analysis ...

The use of the nucleic acid platform for antigen delivery has expanded rapidly in the past decade, highlighted by the development and deployment of several nucleic acid vaccines for SARS-CoV-2 and the ...

A FUNDRAISING campaign has been launched to send a woman diagnosed with an aggressive and incurable brain cancer to Germany for ...

A campaign to raise over £100,000 has been launched to help a Skipton teacher and devoted mum who is suffering from brain cancer.